David Meeker - Articles and news items


Genzyme and Alnylam expand collaboration on rare genetic diseases

Industry news / 13 January 2014 / Sanofi

Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates…

Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

Industry news / 3 October 2013 / Sanofi

Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden…

Genzyme logo

European Commission approves Genzyme’s once-daily, oral multiple sclerosis treatment Aubagio® (teriflunomide)

Industry news, News / 30 August 2013 / Sanofi

Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)…


Sanofi appoints Carsten Hellmann and David Meeker to the Executive Committee

Industry news, News / 31 July 2013 / Sanofi

Sanofi announced the appointment of two new members to the Executive Committee, effective September 1st, 2013…

Genzyme logo

Genzyme receives positive CHMP opinion for LEMTRADA™ in Europe

Industry news, News / 28 June 2013 / Sanofi

“Today’s CHMP opinions set the stage for the approval of two important new treatment options…”

Genzyme logo

Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study

Industry news, News / 25 April 2013 / Sanofi

Genzyme announced positive top-line results from the TOPIC trial for AUBAGIO…

Genzyme logo

Effect of Genzyme’s LEMTRADA maintained in patients beyond two-year pivotal MS studies

Industry news / 21 March 2013 / Sanofi

Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)…

Genzyme logo

Genzyme and Isis announce FDA approval of KYNAMRO™ injection for the treatment of HoFH

Industry news, News / 29 January 2013 / Sanofi

“Today’s FDA approval of KYNAMRO is great news…”

Genzyme logo

Genzyme’s LEMTRADA™ application for MS accepted for review by the FDA

Industry news, News / 28 January 2013 / Sanofi

Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.

Genzyme logo

Genzyme and Isis provide update on CHMP opinion on KYNAMRO™ (mipomersen)

Industry news, News / 14 December 2012 / Sanofi

“We are disappointed by the Committee’s recommendation…”

Genzyme logo

Genzyme announces publication of LEMTRADA (alemtuzumab) pivotal studies in The Lancet

Industry news, News / 31 October 2012 /

Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications…


FDA Advisory Committee recommends KYNAMRO™ for homozygous familial hypercholesterolemia

Industry news, News / 18 October 2012 / Sanofi

“We are very encouraged by the support for KYNAMRO…”

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...